Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. More Details
No risks detected for DIM from our risk checks.
Outstanding track record with excellent balance sheet.
Share Price & News
How has Sartorius Stedim Biotech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DIM is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: DIM's weekly volatility (4%) has been stable over the past year.
7 Day Return
FR Life Sciences
1 Year Return
FR Life Sciences
Return vs Industry: DIM exceeded the French Life Sciences industry which returned 46.9% over the past year.
Return vs Market: DIM exceeded the French Market which returned 48.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Sartorius Stedim Biotech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StIs Sartorius Stedim Biotech (EPA:DIM) Using Too Much Debt?
1 month ago | Simply Wall StSartorius Stedim Biotech S.A.'s (EPA:DIM) CEO Will Probably Have Their Compensation Approved By Shareholders
2 months ago | Simply Wall StHere's What Sartorius Stedim Biotech S.A.'s (EPA:DIM) Shareholder Ownership Structure Looks Like
Is Sartorius Stedim Biotech undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: DIM (€359.7) is trading above our estimate of fair value (€158.68)
Significantly Below Fair Value: DIM is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: DIM is poor value based on its PE Ratio (83.4x) compared to the European Life Sciences industry average (56.7x).
PE vs Market: DIM is poor value based on its PE Ratio (83.4x) compared to the French market (24.6x).
Price to Earnings Growth Ratio
PEG Ratio: DIM is poor value based on its PEG Ratio (10.2x)
Price to Book Ratio
PB vs Industry: DIM is overvalued based on its PB Ratio (21.7x) compared to the XE Life Sciences industry average (6.1x).
How is Sartorius Stedim Biotech forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DIM's forecast earnings growth (8.2% per year) is above the savings rate (0.4%).
Earnings vs Market: DIM's earnings (8.2% per year) are forecast to grow slower than the French market (19.3% per year).
High Growth Earnings: DIM's earnings are forecast to grow, but not significantly.
Revenue vs Market: DIM's revenue (14.5% per year) is forecast to grow faster than the French market (6.8% per year).
High Growth Revenue: DIM's revenue (14.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DIM's Return on Equity is forecast to be high in 3 years time (23.7%)
How has Sartorius Stedim Biotech performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DIM has high quality earnings.
Growing Profit Margin: DIM's current net profit margins (18.6%) are higher than last year (16.7%).
Past Earnings Growth Analysis
Earnings Trend: DIM's earnings have grown significantly by 20.3% per year over the past 5 years.
Accelerating Growth: DIM's earnings growth over the past year (56.8%) exceeds its 5-year average (20.3% per year).
Earnings vs Industry: DIM earnings growth over the past year (56.8%) exceeded the Life Sciences industry 48.8%.
Return on Equity
High ROE: DIM's Return on Equity (25.9%) is considered high.
How is Sartorius Stedim Biotech's financial position?
Financial Position Analysis
Short Term Liabilities: DIM's short term assets (€1.1B) exceed its short term liabilities (€708.0M).
Long Term Liabilities: DIM's short term assets (€1.1B) exceed its long term liabilities (€1.0B).
Debt to Equity History and Analysis
Debt Level: DIM's debt to equity ratio (34.9%) is considered satisfactory.
Reducing Debt: DIM's debt to equity ratio has increased from 13.7% to 34.9% over the past 5 years.
Debt Coverage: DIM's debt is well covered by operating cash flow (93.3%).
Interest Coverage: DIM's interest payments on its debt are well covered by EBIT (18.4x coverage).
What is Sartorius Stedim Biotech current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: DIM's dividend (0.19%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.33%).
High Dividend: DIM's dividend (0.19%) is low compared to the top 25% of dividend payers in the French market (3.94%).
Stability and Growth of Payments
Stable Dividend: DIM is not paying a notable dividend for the French market, therefore no need to check if payments are stable.
Growing Dividend: DIM is not paying a notable dividend for the French market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: DIM is not paying a notable dividend for the French market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DIM's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Joachim Kreuzburg (55 yo)
Dr. rer. pol. Joachim Kreuzburg serves as the Chairman and Chief Executive Officer at Sartorius Stedim Biotech GmbH. Dr. rer. pol. Kreuzburg has been the Chairman of Executive Board at Sartorius Aktiengese...
CEO Compensation Analysis
Compensation vs Market: Joachim's total compensation ($USD4.31M) is about average for companies of similar size in the French market ($USD3.92M).
Compensation vs Earnings: Joachim's compensation has increased by more than 20% in the past year.
Experienced Board: DIM's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Sartorius Stedim Biotech S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Sartorius Stedim Biotech S.A.
- Ticker: DIM
- Exchange: ENXTPA
- Founded: 1870
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: €33.157b
- Shares outstanding: 92.18m
- Website: https://www.sartorius.com
Number of Employees
- Sartorius Stedim Biotech S.A.
- Zone Industrielle Les Paluds
- Avenue de Jouques – CS 91051
- Provence-Alpes-Côte d'Azur
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; biore...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 18:31|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.